Molecular Markers of Amnestic Mild Cognitive Impairment among Mexican Americans

Journal of Alzheimer's Disease

Volumn 49, Issue 1, 2015, Pages 221-228

  Edwards, Melissa ^a   Hall, James ^a   Williams, Benjamin ^b   Johnson, Leigh ^a,c   O'Bryant, Sid ^a,c  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Amnestic; biomarker; Mexican American; mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; PROTEOME;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL DEMENTIA RATING; COMPARATIVE STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC ACCURACY; DIET RESTRICTION; DISEASE SEVERITY; FEMALE; HEALTH DISPARITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEXICAN AMERICAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PARTICIPATORY RESEARCH; PREDICTION; PRIORITY JOURNAL; RANDOM FOREST; TRAIL MAKING TEST; AREA UNDER THE CURVE; BLOOD; EPIDEMIOLOGY; ETHNOLOGY; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; SENSITIVITY AND SPECIFICITY; UNITED STATES;

AGED; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOMARKERS; FEMALE; HUMANS; MALE; MEXICAN AMERICANS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PROTEOME; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84948686370     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150553     Document Type: Article

References (50)

1. US Census Bureau. American Fact Finder. 2004. Available at http://www.census.gov/.
2. Novak K, Riggs JA, Alzheimer's Association (2004) Hispanics/Latinos and Alzheimer's disease. Alzheimer's Association. Available at http://www.alz.org/Downloads/HispanicReportEnglish.pdf
3. O'Bryant SE, Humphreys J, Schiffer R, Sutker P (2007) Presentation of Mexican Americans to a memory disorder clinic. J Psychopathol Behav Assess 29, 137-140.
4. O'Bryant SE, Johnson LA, Reisch J, Edwards M, Hall J, Barber R, Devous MD, Royall D, Singh M(2013) Risk factors for mild cognitive impairment among Mexican Americans. Alzheimers Dement 9, 622-631.
5. O'Bryant S, Johnson L, Balldin V, Edwards M, Barber R, Williams B, Devous M, Cushings B, Knebl J, Hall J (2012) Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 33, 373-379.
6. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lonneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjogren M, Hu W, Lovestone S, Karsdal MA, Weiner MW, for the Blood Based Biomarker Interest, Group (2013) The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10, 115-131.
7. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanskaa L, De Santi S, Zinkowski R, Mehta PD, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudindal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30, 682-690.
8. Dickerson BC, Wolk DA, Alzheimer's Disease Neuroimaging, Initiative (2013) Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-beta and tau. Front Aging Neurosci 5, 55.
9. Davatzikos C, Bhatt P, Shaw L, Batmanghelich K, Trojanowski J (2011) Prediction ofMCItoADconversion, via MRI, CSF biomarkers and pattern classification. Neurobiol Aging 32, 2322.e19-27.
10. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE, for the Alzheimer's Disease Neuroimaging, Initiative (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Gen Psychiatry 68, 961-969.
11. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
12. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27, 394-401.
13. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ, the Alzheimer's Disease Neuroimaging, Initiative (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1207-1218.
14. Masdeu JC, Zubieta JL, Arbizu J (2005) Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci 236, 55-64.
15. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC, the Alzheimer's Disease Neuroimaging, Initiative (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6, 347-361.
16. Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr (2008) MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 70, 512-520.
17. Oh ES, Mielke MM, Rosenberg PB, Jain A, Fedarko NS, Lyketsos CG, Mehta P (2010) Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-in plasma. J Alzheimers Dis 21, 769-773.
18. Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, Wang Y, Deng Y-L, Ren R-J, Xu W, Ma J-F, Zhang Y-N, Zhao AH, Chen S-D, Jia W (2014) Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J Proteome Res 13, 2649-2658.
19. Panachamnong N, Methapatara P, Sungkarat S, Taneyhill K, Intasai N (2014) Clusterin as a blood biomarker for the diagnosis of mild cognitive impairment and Alzheimer's disease. J Nat Sci 13, 331-344.
20. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, Kraut M, Ferrucci L, Davatzikos C, Lovestone S, Resnick SM (2012) Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 59, 212-217.
21. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, et al. (2010) Meta-analysis confirms CR1, CLU, andPICALM as Alzheimer's disease risk loci and reveals interactions with ApoEe4 genotypes. Arch Neurol 67, 1473-1484.
22. Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, Jimenez-Velazquez IZ, Rogaeva E, St George-Hyslop PH, Mayeux R (2011) Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 68, 320-328.
23. Royall DR, Palmer RF, for the Texas Alzheimer's Research, Care, Consortium (2014) Does ethnicity moderate dementia's biomarkers Neurobiol Aging 35, 336-344.
24. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R, Texas Alzheimer's Research, Consortium (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
25. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, for the Texas Alzheimer's Research, Care Consortium, for the Alzheimer's Disease Neuroimaging, Initiative (2011) A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS One 6, e28092.
26. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K, Diaz-Arrastia R, Texas Alzheimer's Research, Care, Consortium (2011) A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
27. Johnson LA, Gamboa A, Vintimilla R, Cheatwood AJ, Grant A, Trivedi A, Edwards M, Hall JR, O'Bryant SE (2015) Comorbid depression and diabetes as a risk for mild cognitive impairment and Alzheimer's disease in elder Mexican Americans. J Alzheimers Dis 47, 129-136.
28. Szerlip HM, Edwards ML, Williams BJ, Johnson LA, Vintimilla RM, O'Bryant SE (2015) Association of cognitive impairment with chronic kidney disease in Mexican Americans. J Am Geriatr Soc. in press.
29. Petersen RC (2003) Mild Cognitive Impairment: Aging to Alzheimer's Disease, Oxford University Press, New York.
30. Ivnik R, Malec JF, Smith GE (1992) Mayo's Older Americans Normative Studies: WAIS-R norms for age 56 to 97. Clin Neuropsychol 6, 1-30.
31. Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological Assessment, 4th ed, Oxford University Press, Oxford.
32. Royall DR, Cordes JA, Polk M (1998) CLOX: An executive clock drawing task. J Neurol Neurosurg Psychiatry 64, 588-594.
33. Strauss E, Sherman EMS, Spreen O (2006) A Compendium of Neuropsychological Tests: Administration, norms, and commentary, 3rd ed, Oxford University Press, Oxford.
34. Wechsler D (1997) Wechsler Memory Scale. Third edition manual, The Psychological Corporation, San Antonio.
35. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
36. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414.
37. O'Bryant SE, Lacritz LH, Hall J, Waring SC, Chan W, Khodr ZG, Massman PJ, Hobson V, Cullum CM (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the National Alzheimer's Coordinating Center database. Arch Neurol 67, 746-749.
38. O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman R, Fagan A, Oberoi P, Umek R, Weiner M, Grammas P, Posner H, Martins R (2014) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 11, 549-560.
39. Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lindberg RL, Petzold A (2010) A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 220, 114-119.
40. R Development Core Team (2009) R: A language and environment for statistical computing. Accessed at http://www.R-project.org.
41. Breiman L (2001) Random forests. Mach Learn 45, 5-32.
42. O'Bryant SE, Lucas JA(2007) Estimating the predictive value of the Test of Memory Malingering: An illustrative example for clinicians. Clin Neuropsychol 20, 533-540.
43. O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R, for the Texas Alzheimer's Research and Care Consortium (TARCC) (2013) Biomarkers of Alzheimer's disease among Mexican Americans. J Alzheimers Dis 34, 841-849.
44. Weniger SC, Yankner BA (2001) Inflammation and Alzheimer's disease: The good, the bad, and the ugly. Nat Med 7, 527-528.
45. Aisen PS (1997) Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies. Gerontology 43, 143-149.
46. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R (2009) Decreased C-reactive protein levels in Alzheimer's disease. J Geriatr Psychiatry Neurol 23, 49-53.
47. Halliday G, Robinson SR, Shepherd C, Kril J (2000) Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 27, 1-8.
48. Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM (2012) Plasma signaling proteins in persons at genetic risk for Alzheimer disease: Influence of APOE genotype. Arch Neurol 69, 757-764.
49. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, Biomarkers Consortium Alzheimer's Disease Plasma Proteomics, Project (2012) Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69, 1310-1317.
50. Faison WE, Schultz SK, Aerssens J, Alvidrez J, Anand R, Farrer LA, Jarvik L, Manly J, McRae T, Murphy G Jr, Olin JT, Regier D, Sano M, Mintzer JE (2007) Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: Challenges for the future. Int Psychogeriatr 19, 539-558.